SB
SelSym Biotech develops SymClot, a platelet-mimetic therapy that enhances hemorrhage control during trauma and surgical procedures while addressing critical platelet supply shortages. Their Hemostatic Healing Hydrogels (H3) provide targeted wound healing support, improving patient outcomes and minimizing complications associated with traditional treatments.
Updated 20 months ago
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NI
Funding rounds are not available yet.
Founders
Product
Features
- SelSym Biotech develops SymClot, a platelet-mimetic therapy that enhances hemorrhage control during trauma and surgical procedures while addressing critical platelet supply shortages. Their Hemostatic Healing Hydrogels (H3) provide targeted wound healing support, improving patient outcomes and minimizing complications associated with traditional treatments.